Truist initiated coverage on Nurix Therapeutics with a new price target
$NRIX
Biotechnology: Pharmaceutical Preparations
Health Care
Truist initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $36.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $35.00 | Buy | UBS |
| 10/11/2024 | $41.00 | Buy | Jefferies |
| 9/6/2024 | $26.00 | Outperform | Robert W. Baird |
| 7/31/2024 | $36.00 | Buy | Truist |
| 6/26/2023 | $25.00 | Outperform | Oppenheimer |
| 3/9/2023 | $20.00 | Overweight | Barclays |
| 2/28/2023 | $25.00 | Outperform | Oppenheimer |
| 10/11/2022 | $11.00 | Equal-Weight | Morgan Stanley |
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST) SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical d
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain. The oral presentation at EHA2024 will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractor
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcast conference call on June 16 following the data presentation at EHA (details to follow) SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory
424B5 - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
S-8 - Nurix Therapeutics, Inc. (0001549595) (Filer)
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the European Medicines Agency (EMA) has granted PRIME designation for NX-5948, a highly selective degrader of Bruton's tyrosine kinase (BTK), for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of preclinical data, including mechanism of action and relevant disease models, from two pipeline programs: NX-5948 and GS-6791. NX-5948 is Nurix's proprietary, orally available, brain penetrant Bruton's tyrosine kinase (BTK) degrader, which is being developed for the potential treatment of inflammation and autoimmune diseases in addition to its ongoing Phase 1b trial in patients with B-cell malignancies. GS-6791 is a
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that data will be presented from its two Bruton's tyrosine kinase (BTK) degrader programs, NX-5948 and NX-2127, in two oral presentations and one poster at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA. Oral Presentation Details: Title: Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic L
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
UBS initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $35.00
Jefferies initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $41.00
Robert W. Baird resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $26.00
Nurix Therapeutics (NASDAQ:NRIX) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7 0 0 0 Last 30D 0 2 0 0 0 1M Ago 3 3 0 0 0 2M Ago 0 1 0 0 0 3M Ago 2 1 0 0 0 Analysts have set 12-month price targets for Nurix Therapeutics, revealing an average target of $29.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 4.69% increase, the current
JP Morgan analyst Eric Joseph maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $31 to $34.
Barclays analyst Peter Lawson maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $20 to $31.
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets. "I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company's development and execute on our plan to advance NX-5948 into pivotal clinical testing in 2025 and prepare for future
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G. O'Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix. "I am delighted to announce the promotions of both Paula and Pasit, which recognize their significant and ongoing leadership in advancing our pipeline of novel medicines and particularly in accelerating our NX-5948 program in chronic lymphocytic leukemia and non-Hodgkin's lymphoma," said Arthur T. Sa
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix's two first-in-class BTK degraders in 2023 Clinical data update planned for Nurix's first-in-class CBL-B inhibitor in 2023 Significant progress made across deep pipeline of preclinical candidates SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated mil